Li and colleagues recently demonstrated in Cancer Cell that the histamine receptor H1 (HRH1) axis could serve both as therapeutic targets for enhancing immunotherapy response and predictive biomarker of T cell exhaustion and therapeutic effectiveness in cancer immunotherapy [1] (Fig. 1). This evidence concerns the gene HRH1 and cancer.